Company Description

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products.

The company’s lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

It is also involved in the medical scientific research and development activities, as well as operates investment firms.

The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024.

PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

PMGC Holdings Inc.

Country	United States
Founded	2020
IPO Date	Nov 21, 2023
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Graydon Bensler

Contact Details

Address: 120 Newport Center Drive, Suite 249 Newport Beach, California 92660 United States
Phone	866 445 4886
Website	pmgcholdings.com

Stock Details

Ticker Symbol	ELAB
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.00
CIK Code	0001840563
CUSIP Number	73017P300
ISIN Number	US73017P3001
Employer ID	85-1399981
SIC Code	2834

Key Executives

Name	Position
Graydon Bensler C.F.A.	Chief Executive Officer, Chief Financial Officer, Secretary and Director
Braeden William Lichti	Executive Chairman of the Board

Latest SEC Filings

Date	Type	Title
Oct 3, 2025	SCHEDULE 13G/A	Filing
Sep 30, 2025	PRE 14C	Filing
Sep 29, 2025	SCHEDULE 13G	Filing
Sep 29, 2025	8-K	Current Report
Sep 22, 2025	S-1	General form for registration of securities under the Securities Act of 1933
Sep 17, 2025	8-K	Current Report
Sep 4, 2025	8-K	Current Report
Aug 29, 2025	SCHEDULE 13G/A	Filing
Aug 26, 2025	DEF 14C	Filing
Aug 25, 2025	8-K	Current Report

View All SEC Filings